Successfully passed the first clinical trial of cancer vaccine using the invention of Polish experts – said at a press conference in Warsaw, Jacek Jemielity, Professor at the University of Warsaw.
Professor Jemielity said that the drug successfully passed the first phase of clinical trials, and is designed to treat melanoma, one of the deadliest types of skin cancer.
Research the next phase on this tool can be completed in 2-3 years. This success has allowed our invention interested pharmaceutical companies that also want to use it for new anticancer drugs. In the future due to our reaching may occur some drugs of the new generation reported.
the Director of the University’s Technology Transfer Center Dr. Robert Dwiliński explained that an invention developed by scientists at the University of Warsaw lies in the fact that the change in mRNA, which can be used for gene therapy.
this Achievement can be compared to the invention of radium, which at first had no practical application, and then began the use of radioactivity in medicine, – said Dr. Dwiliński.
Professor Jemielity, who works in the Department of Biophysics p R I in the Centre of New Technologies University of Warsaw, he explained that the mRNA is a recipe for certain proteins. This backup genes that carry the cells of information needed for the production of the protein.
the Trouble is that the natural mRNA is not stable and rapidly undergoes degradation in the cell. Must also compete in a cage with other molecules of mRNA that reached its connection with the factor that triggers the conversion necessary for the production of protein. So you can use the mRNA to therapy, it was necessary to stabilize, – said the expert.
Scientists from the UW changed the structure of the end molecules of the mRNA (the so-called kapem 5'), which is universal: in the completion of all mRNAs, irrespective of what’s the recipe for the protein data.
One of the elements of the tray 5 of' the bridge trifosforanowy. We changed only one atom, the oxygen atom on the sulfur atom, but that was enough to mRNAs with the same analogue of the Kapu was four times stronger and was observed several times stronger than the affinity of the factor initiating the move, – explained the Professor. Jemielity.
the Expert added that it is surprising that so little change was enough to get a great effect, especially since a molecule of mRNA contains about 80 thousand. atoms. Worked many specialists from all over the world, but it is managed language researchers, assisted by scientists from Louisiana state University.
This revolutionary modification called beta-S-ARCA. Soon the UW researchers found that there is a second method of stabilization of the mRNA, which was called beta-B-ARCA.
Both so interested in German experts from the University of Mainz, and belonging to him, a biotechnology company BioNTech. “This company became an investor of both our development and has assumed the financial risks of their use in practice”, stressed Dr. Dwiliński.
German, the company also launched the first clinical study on a drug that contains the constant mRNA developed by Polish scientists. “We, in turn, we control the synthesis of S-ARCA to a greater extent on gram scale, which increased the interest to this invention pharmaceutical corporations,” said the Professor. Jemielity.
BioNTech at the end of 2015. signed a contract worth $ 300 million with Sanofi in 2016. owned by Roche biotech company Genetech in San Francisco ($ 310 million). The two oil companies intend to use a Russian invention for the development of new drugs (immunoterapeutyków in the treatment of cancer – PAP) on the basis of the modified mRNA.
the Director of the Centre of New Technologies University of Warsaw, Professor Piotr Węgleński said at a meeting with journalists that neither the Polish firm was not interested in the use of inventions of scientists in the UW studies on their own drug.
according to Professor Jemielity development of a new biological drug and its introduction on the market currently worth $ 2 billion.
Dr. Dwiliński said that Warsaw University has a guaranteed income from each of the contract with investors, as well as from the sale of drugs and therapy, will use modified mRNA Polish researchers. Work on it lasted for almost 35 years, was started in the early 80-ies. XX century, took part in them many researchers.
(abs)
No comments:
Post a Comment